Compare Novartis AG (NVS) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SoundHound AI Inc — how do they compare? Novartis AG trades at $152.68 (market cap $295.37B), while SoundHound AI Inc trades at $7.37 (market cap $3.29B). The key difference: Novartis AG is far larger — about 89.8× SoundHound AI Inc's market cap, and Novartis AG pays a 3.07% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| NVS | SOUN | |
|---|---|---|
Market Cap | $295.37B | $3.29B |
Sector | Health | Technology |
52-Week High | $168.62 | $21.40 |
52-Week Low | $119.31 | $5.70 |
Enterprise Value | $336.69B | $3.09B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
SoundHound AI (SOUN) trades at $7.395, down 0.87% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, revenue grew 45% year-over-year to $61.9 million, and the company raised its 2026 revenue guidance, driven by its OASYS platform. However, the stock faces headwinds from negative net income margins and high cash burn.
The outlook is cautiously optimistic with 75% of analysts rating it Buy and a $8.50 consensus target, but profitability challenges and premium valuations pose risks. Key catalysts include the pending LivePerson acquisition and OASYS adoption, while execution on path to profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
